Company intelligence / Profile preview
Sonnet BioTherapeutics
Princeton, New Jersey, United Statessonnetbio.com ↗
- Ownership
- Public · SONN
- Employees
- ~13
- Development stage
- Phase 1
01
Overview
Sonnet has reported positive interim results from its Phase 1 SB101 trial for SON-1010, with 48% of evaluable patients achieving stable disease at four months and one patient showing a partial response at the maximum tolerated dose. The company is progressing with combination trials of SON-1010 with atezolizumab for platinum-resistant ovarian cancer and with trabectedin for advanced soft-tissue sarcomas. They are also preparing to initiate a clinical trial for SON-1210 for advanced solid tumors and metastatic pancreatic cancer in the first half of 2025[5][7].
- Therapeutic areas
- OncologyEndocrinologyNeurology
- Modalities
- Biologic drugscytokinespeptidesantibodiesvaccines
- Industry
- Biotech
02
Drug pipeline
15 assets14 more assets in the full pipeline.
03
Partnerships
Roche/Genentech (for SON-1010 with atezolizumab)Sarcoma Oncology Center (for SON-1210)New Life Therapeutics Pte, Ltd. (for SON-080)Alkem Laboratories (for SON-080 in India)
Beyond the preview
Go deeper on Sonnet BioTherapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sonnet BioTherapeutics.